Swiss pharma hopes to bounce back from Q1 sales disappointment
Otezla cheap and convenient, but less effective than rivals, says NICE.
NICE says Otezla’s bargain price offsets lower efficacy
R-Pharm has a mid-stage rival.
Russian rival to GSK/Janssen’s RA drug revealed
Gamble on opicinumab looks unlikely to pay off.
Biogen eyeing big-selling biosimilars as MS drug fails
But attendees warned to expect “oceanic” weather.
Janssen’s RA candidate among hot topics at EULAR